709 related articles for article (PubMed ID: 25070294)
1. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
3. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
[TBL] [Abstract][Full Text] [Related]
4. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
6. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
7. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of BRAF mutations in localized cutaneous melanoma.
Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
Wolfe AR; Chablani P; Siedow MR; Miller ED; Walston S; Kendra KL; Wuthrick E; Williams TM
Radiat Oncol; 2021 Sep; 16(1):181. PubMed ID: 34537078
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.
Larsen AC; Dahmcke CM; Dahl C; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
JAMA Ophthalmol; 2015 Nov; 133(11):1295-303. PubMed ID: 26425792
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?
Barbour S; Mark Smithers B; Allan C; Bayley G; Thomas J; Foote M; Burmeister B; Barbour AP
Ann Surg Oncol; 2015 Nov; 22(12):4052-9. PubMed ID: 25582744
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
17. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
18. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
20. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]